Fine-Tuning Antitumor Responses Through the Control of Galectin–Glycan Interactions: An Overview

Methods in Molecular Biology

Volumn 677, Issue , 2011, Pages 355-374

  Salatino, Mariana ^a   Rabinovich, Gabriel A ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cancer; Galectins; Glycosylation; Tumor immunity; Tumor microenvironment

Indexed keywords

GALECTIN; LECTIN; POLYSACCHARIDE;

ADAPTIVE IMMUNITY; ANIMAL; ARTICLE; CELL CULTURE; CELL MOTION; DRUG INTERACTION; GLYCOSYLATION; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ADAPTIVE IMMUNITY; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; DRUG INTERACTIONS; GALECTINS; GLYCOSYLATION; HUMANS; LECTINS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASMS; POLYSACCHARIDES; RATS; TUMOR CELLS, CULTURED; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 79952202168     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-869-0_23     Document Type: Chapter

References (111)

1. Ohtsubo K and Marth JD. (2006) Glycosylation in cellular mechanisms of health and disease. Cell 126: 855–867.
2. van Kooyk Y and Rabinovich GA. (2008) Protein–glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 9: 593–601.
3. Rabinovich GA and Toscano MA. (2009) Turning ‘sweet’ on immunity: galectin– glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 9: 338–352.
4. Hakomori S. (2002) Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 99: 10231–10233.
5. Lau KS and Dennis JW. (2008) N-Glycans in cancer progression. Glycobiology 18: 750–760.
6. Kim YJ and Varki A. (1997) Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 14: 569–576.
7. Dube DH and Bertozzi CR. (2003) Metabolic oligosaccharide engineering as a tool for glycobiology. Curr Opin Chem Biol 7: 616–625.
8. Dube DH and Bertozzi CR. (2005) Glycans in cancer and inflammation – potential for therapeutics and diagnostics. Nat Rev Drug Discov 4: 477–488.
9. Keppler OT, Horstkorte R, Pawlita M, et al. (2001) Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology 11: 11R–18R.
10. Prescher JA, Dube DH and Bertozzi CR. (2004) Chemical remodelling of cell surfaces in living animals. Nature 430: 873–877.
11. Hollingsworth MA and Swanson BJ. (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4: 45–60.
12. Hakomori S. (2000) Traveling for the gly-cosphingolipid path. Glycoconj J 17: 627–647.
13. Rabinovich GA, Toscano MA, Jackson SS, et al. (2007) Functions of cell surface galectin-glycoprotein lattices. Curr Opin Struct Biol 17: 513–520.
14. Yang RY, Rabinovich GA and Liu FT. (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10: e17.
15. Rabinovich GA and Ilarregui JM. (2009) Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol Rev 230: 144–159.
16. Brewer CF, Miceli MC and Baum LG. (2002) Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr Opin Struct Biol 12: 616–623.
17. Laderach DJ, Compagno D, Toscano MA, et al. (2010) Dissecting the signal transduction pathways triggered by galectin–glycan interactions in physiological and pathological settings. IUBMB Life 62(1):1–13.
18. Kubach J, Lutter P, Bopp T, et al. (2007) Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 110:1550–1558.
19. Hirabayashi J, Hashidate T, Arata Y, et al. (2002) Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 1572: 232–254.
20. Stowell SR, Arthur CM, Mehta P, et al. (2008) Galectin-1,-2, and-3 exhibit differential recognition of sialylated glycans and blood group antigens. J Biol Chem 283: 10109–10123.
21. Liu FT and Rabinovich GA. (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29–41.
22. Salatino M, Croci DO, Bianco GA, et al. (2008) Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert Opin Biol Ther 8: 45–57.
23. Elola MT, Wolfenstein-Todel C, Troncoso MF, et al. (2007) Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 64: 1679–1700.
24. Perillo NL, Pace KE, Seilhamer JJ, et al. (1995) Apoptosis of T cells mediated by galectin-1. Nature 378: 736–739.
25. Thijssen VL, Postel R, Brandwijk RJ, et al. (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 103: 15975–15980.
26. Le Mercier M, Fortin S, Mathieu V, et al. (2009) Galectin 1 proangiogenic and promi-gratory effects in the Hs683 oligodendro-glioma model are partly mediated through the control of BEX2 expression. Neoplasia 11: 485–496.
27. Rubinstein N, Alvarez M, Zwirner NW, et al. (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5: 241–251.
28. Juszczynski P, Ouyang J, Monti S, et al. (2007) The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 104: 13134–13139.
29. Gandhi MK, Moll G, Smith C, et al. (2007) Galectin-1 mediated suppression of Epstein– Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 110: 1326–1329.
30. Valenzuela HF, Pace KE, Cabrera PV, et al. (2007) O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res 67: 6155–6162.
31. Le QT, Shi G, Cao H, et al. (2005) Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23: 8932–8941.
32. Peng W, Wang HY, Miyahara Y, et al. (2008) Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 68: 7228–7236.
33. Zubieta MR, Furman D, Barrio M, et al. (2006) Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 168: 1666–1675.
34. Klibi J, Niki T, Riedel A, et al. (2009) Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein–Barr virus-infected nasopharyngeal carcinoma cells. Blood 113: 1957–1966.
35. Zhu C, Anderson AC, Schubart A, et al. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6: 1245–1252.
36. Nagahara K, Arikawa T, Oomizu S, et al. (2008) Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 181: 7660–7669.
37. Allione A, Wells V, Forni G, et al. (1998) Beta-galactoside-binding protein (beta GBP) alters the cell cycle, up-regulates expression of the alpha-and beta-chains of the IFN-gamma receptor, and triggers IFN-gamma-mediated apoptosis of activated human T lymphocytes. J Immunol 161: 2114–2119.
38. Hahn HP, Pang M, He J, et al. (2004) Galectin-1 induces nuclear translocation of endonuclease G in caspase-and cytochrome c-independent T cell death. Cell Death Differ 11: 1277–1286.
39. Brandt B, Buchse T, Abou-Eladab EF, et al. (2008) Galectin-1 induced activation of the apoptotic death-receptor pathway in human Jurkat T lymphocytes. Histochem Cell Biol 129: 599–609.
40. Matarrese P, Tinari A, Mormone E, et al. (2005) Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem 280: 6969–6985.
41. Vespa GN, Lewis LA, Kozak KR, et al. (1999) Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J Immunol 162: 799–806.
42. Rabinovich GA, Alonso CR, Sotomayor CE, et al. (2000) Molecular mechanisms implicated in galectin-1-induced apoptosis: activation of the AP-1 transcription factor and downregulation of Bcl-2. Cell Death Differ 7: 747–753.
43. Stowell SR, Karmakar S, Arthur CM, et al. (2009) Galectin-1 induces reversible phosphatidylserine exposure at plasma membrane. Mol Biol Cell 20: 1408–1418.
44. Pang M, He J, Johnson P, et al. (2009) CD45-mediated fodrin cleavage during galectin-1 T cell death promotes phagocytic clearance of dying cells. J Immunol 182: 7001–7008.
45. Toscano MA, Bianco GA, Ilarregui JM, et al. (2007) Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8: 825–834.
46. Earl LA, Bi S and Baum LG. (2010) N-and O-glycans modulate galectin-1 binding, CD45 signaling and T cell death. J Biol Chem 285: 2232–2244.
47. Galvan M, Tsuboi S, Fukuda M, et al. (2000) Expression of a specific glycosyltransferase enzyme regulates T cell death mediated by galectin-1. J Biol Chem 275: 16730–16737.
48. Amano M, Galvan M, He J, et al. (2003) The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J Biol Chem 278: 7469–7475.
49. Pace KE, Lee C, Stewart PL, et al. (1999) Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol 163: 3801–3811.
50. Sturm A, Lensch M, Andre S, et al. (2004) Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol 173: 3825–3837.
51. Bi S, Earl LA, Jacobs L, et al. (2008) Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J Biol Chem 283: 12248–12258.
52. Kashio Y, Nakamura K, Abedin MJ, et al. (2003) Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 170: 3631–3636.
53. Hsu DK, Yang RY, Pan Z, et al. (2000) Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 156: 1073–1083.
54. Yoshii T, Fukumori T, Honjo Y, et al. (2002) Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 277: 6852–6857.
55. Kim HR, Lin HM, Biliran H, et al. (1999) Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 59: 4148–4154.
56. Oka N, Nakahara S, Takenaka Y, et al. (2005) Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res 65: 7546–7553.
57. Lee YJ, Song YK, Song JJ, et al. (2003) Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp Cell Res 288: 21–34.
58. Stillman BN, Hsu DK, Pang M, et al. (2006) Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 176: 778–789.
59. Dong S and Hughes RC. (1996) Galectin-3 stimulates uptake of extracellular Ca2+ in human Jurkat T-cells. FEBS Lett 395: 165–169.
60. Fukumori T, Takenaka Y, Yoshii T, et al. (2003) CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 63: 8302–8311.
61. Yang RY, Hsu DK and Liu FT. (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 93: 6737–6742.
62. Yu F, Finley RL, Jr, Raz A, et al. (2002) Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 277: 15819–15827.
63. Matarrese P, Fusco O, Tinari N, et al. (2000) Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85: 545–554.
64. Fukumori T, Takenaka Y, Oka N, et al. (2004) Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 64: 3376–3379.
65. Akahani S, Nangia-Makker P, Inohara H, et al. (1997) Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57: 5272–5276.
66. Polyak K, Xia Y, Zweier JL, et al. (1997) A model for p53-induced apoptosis. Nature 389: 300–305.
67. Bernerd F, Sarasin A and Magnaldo T. (1999) Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocytes. Proc Natl Acad Sci USA 96: 11329–11334.
68. Kuwabara I, Kuwabara Y, Yang RY, et al. (2002) Galectin-7 (PIG1) exhibits proapoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem 277: 3487–3497.
69. Gendronneau G, Sidhu SS, Delacour D, et al. (2008) Galectin-7 in the control of epidermal homeostasis after injury. Mol Biol Cell 19: 5541–5549.
70. Tribulatti MV, Mucci J, Cattaneo V, et al. (2007) Galectin-8 induces apoptosis in the CD4(high)CD8(high) thymocyte subpopulation. Glycobiology 17: 1404–1412.
71. Norambuena A, Metz C, Vicuna L, et al. (2009) Galectin-8 induces apoptosis in Jurkat T cells by phosphatidic acid-mediated ERK1/2 activation supported by protein kinase A down-regulation. J Biol Chem 284: 12670–12679.
72. Rabinovich GA, Modesti NM, Castagna LF, et al. (1997) Specific inhibition of lymphocyte proliferation and induction of apoptosis by CLL-I, a beta-galactoside-binding lectin. J Biochem 122: 365–373.
73. Marth JD and Grewal PK. (2008) Mammalian glycosylation in immunity. Nat Rev Immunol 8: 874–887.
74. Motran CC, Molinder KM, Liu SD, et al. (2008) Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function. Eur J Immunol 38: 3015–3027.
75. Rabinovich GA, Ariel A, Hershkoviz R, et al. (1999) Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 97: 100–106.
76. Rabinovich GA, Daly G, Dreja H, et al. (1999) Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 190: 385–398.
77. Toscano MA, Commodaro AG, Ilarregui JM, et al. (2006) Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2-and T regulatory-mediated anti-inflammatory responses. J Immunol 176: 6323–6332.
78. Stowell SR, Qian Y, Karmakar S, et al. (2008) Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion. J Immunol 180: 3091–3102.
79. Niwa H, Satoh T, Matsushima Y, et al. (2009) Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1 and Th17-mediated skin inflammation. Clin Immunol 132: 184–194.
80. Seki M, Oomizu S, Sakata KM, et al. (2008) Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 127: 78–88.
81. Rabinovich GA, Gabrilovich D and Sotomayor EM. (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267–296.
82. Liu SD, Tomassian T, Bruhn KW, et al. (2009) Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size. J Immunol 182: 5283–5295.
83. Grigorian A, Torossian S and Demetriou M. (2009) T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunol Rev 230: 232–246.
84. Lau KS, Partridge EA, Grigorian A, et al. (2007) Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129: 123–134.
85. Demotte N, Stroobant V, Courtoy PJ, et al. (2008) Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 28: 414–424.
86. Clark AG, Chen S, Zhang H, et al. (2007) Multifunctional regulators of cell growth are differentially expressed in anergic murine B cells. Mol Immunol 44: 1274–1285.
87. Sakaguchi S. (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531–562.
88. Curiel TJ, Coukos G, Zou L, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942–949.
89. Zou W. (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295–307.
90. Garin MI, Chu CC, Golshayan D, et al. (2007) Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 109: 2058–2065.
91. Sugimoto N, Oida T, Hirota K, et al. (2006) Foxp3-dependent and-independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int Immunol 18: 1197–1209.
92. Wang J, Lu ZH, Gabius HJ, et al. (2009) Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J Immunol 182: 4036–4045.
93. Blois SM, Ilarregui JM, Tometten M, et al. (2007) A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 13: 1450–1457.
94. Wang F, Wan L, Zhang C, et al. (2009) Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology 214: 342–349.
95. Guermonprez P, Valladeau J, Zitvogel L, et al. (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20: 621–667.
96. Steinman RM, Hawiger D and Nussenzweig MC. (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21: 685–711.
97. Reis e Sousa C. (2006) Dendritic cells in a mature age. Nat Rev Immunol 6: 476–483.
98. Skoberne M, Beignon AS and Bhardwaj N. (2004) Danger signals: a time and space continuum. Trends Mol Med 10: 251–257.
99. Svensson M, Maroof A, Ato M, et al. (2004) Stromal cells direct local differentiation of regulatory dendritic cells. Immunity 21: 805–816.
100. Awasthi A, Carrier Y, Peron JP, et al. (2007) A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8: 1380–1389.
101. Ilarregui JM, Croci DO, Bianco GA, et al. (2009) Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 10: 981–991.
102. Kotera Y, Shimizu K and Mule JJ. (2001) Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61: 8105–8109.
103. Fulcher JA, Chang MH, Wang S, et al. (2009) Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J Biol Chem 284: 26860–26870.
104. Hirashima M, Kashio Y, Nishi N, et al. (2009) Galectin-9 in physiological and pathological conditions. Glycoconj J 19: 593–600.
105. Dai SY, Nakagawa R, Itoh A, et al. (2005) Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol 175: 2974–2981.
106. Anderson AC, Anderson DE, Bregoli L, et al. (2007) Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318: 1141–1143.
107. Hsu DK, Chernyavsky AI, Chen HY, et al. (2009) Endogenous galectin-3 is localized in membrane lipid rafts and regulates migration of dendritic cells. J Invest Dermatol 129: 573–583.
108. Bernardes ES, Silva NM, Ruas LP, et al. (2006) Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. Am J Pathol 168: 1910–1920.
109. Breuilh L, Vanhoutte F, Fontaine J, et al. (2007) Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells. Infect Immun 75: 5148–5157.
110. Consortium for Functional Glycomics (http://www.functionalglycomics.org).
111. The Japanese Consortium for Glycobiology and Glycotechnology (http://www.jcgg.jp).